Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress
Overview
Neurology
Authors
Affiliations
Studies indicated that mammalian target of rapamycin (mTOR), oxidative stress, and inflammation are involved in the pathophysiology of major depressive disorder (MDD). Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been identified as a novel MDD therapy; however, the antidepressant mechanism is not fully understood. In addition, the effects of ketamine after mTOR inhibition have not been fully investigated. In the present study, we examined the behavioral and biochemical effects of ketamine in the prefrontal cortex (PFC), hippocampus, amygdala, and nucleus accumbens after inhibition of mTOR signaling in the PFC. Male adult Wistar rats received pharmacological mTOR inhibitor, rapamycin (0.2 nmol) or vehicle into the PFC and then a single dose of ketamine (15 mg/kg, i.p.). Immobility was assessed in forced swimming tests, and then oxidative stress parameters and inflammatory markers were evaluated in the brain and periphery. mTOR activation in the PFC was essential to ketamine's antidepressant-like effects. Ketamine increased lipid damage in the PFC, hippocampus, and amygdala. Protein carbonyl was elevated in the PFC, amygdala, and NAc after ketamine administration. Ketamine also increased nitrite/nitrate in the PFC, hippocampus, amygdala, and NAc. Myeloperoxidase activity increased in the hippocampus and NAc after ketamine administration. The activities of superoxide dismutase and catalase were reduced after ketamine administration in all brain areas studied. Inhibition of mTOR signaling pathways by rapamycin in the PFC was required to protect against oxidative stress by reducing damage and increasing antioxidant enzymes. Finally, the TNF-α level was increased in serum by ketamine; however, the rapamycin plus treatment group was not able to block this increase. Activation of mTOR in the PFC is involved in the antidepressant-like effects of ketamine; however, the inhibition of this pathway was able to protect certain brain areas against oxidative stress, without affecting inflammation parameters.
Aguiar-Geraldo J, Canever L, Marino D, Coan C, Possamai-Della T, Pescador B Neurotox Res. 2025; 43(1):5.
PMID: 39833594 DOI: 10.1007/s12640-024-00727-x.
Abnormal Serum BDNF and p-mTOR in MDD in Adolescents with Childhood Trauma.
Zhao X, Jie H, Wang J, Liu Y, Liu Y, Qin F Neuropsychiatr Dis Treat. 2024; 20:1513-1522.
PMID: 39109146 PMC: 11302521. DOI: 10.2147/NDT.S454370.
Cheng Y, Wang X, Yu Y, Gu J, Zhao M, Fu Q Neurochem Res. 2022; 47(11):3318-3330.
PMID: 35978229 DOI: 10.1007/s11064-022-03683-0.
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Kopra E, Mondelli V, Pariante C, Nikkheslat N J Psychopharmacol. 2021; 35(8):934-945.
PMID: 34180293 PMC: 8358579. DOI: 10.1177/02698811211026426.
Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates.
Grolli R, Mingoti M, Bertollo A, Luzardo A, Quevedo J, Reus G Mol Neurobiol. 2021; 58(5):1905-1916.
PMID: 33404981 PMC: 7786865. DOI: 10.1007/s12035-020-02249-x.